GenoMed's West Nile Virus Trial Gaining Publicity
FOR IMMEDIATE RELEASE
Contact:
Dr. David Moskowitz
GenoMed, Inc.
tel. 314-652-0500
July 1, 2004--St. Louis-- GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management(tm) company, announced today that its global trial against West Nile virus encephalitis is gaining publicity.
A link to the Company's trial has appeared on the West Nile virus information page hosted by the Audobon Society, audubon.org
The Company's initial case series of 8 patients from last summer will be published later this month in the medical journal "Current Topics in Medicinal Chemistry."
Since the article was written, the Company has treated 4 more patients with documented West Nile virus encephalitis so that GenoMed's record currently stands at 11-1. All 11 successes have been in patients with an intact immune system. The single failure came in an immunosuppressed patient with chronic leukemia last summer. GenoMed's treatment is therefore not offered to immunosuppressed patients.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "This publicity is coming early enough this summer to hopefully save people's lives. Last summer, word of our trial came out quite late in the season. The July 4th weekend is usually when the West Nile virus epidemic takes off. I'm especially concerned with the situation in Arizona, which has had 37 cases already, and which has such a high proportion of elderly residents. The elderly have the highest mortality from West Nile virus encephalitis. Arizona could be even worse than Colorado was last year."
Anyone can enroll in GenoMed's trial at any time of day or night by clicking on the "West Nile trial" link at genomedics.com, or going directly to
b2i.us
About GenoMed
GenoMed's goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. As a Next Generation Disease Management(tm) company, GenoMed is already marketing its treatments to prevent kidney dialysis due to diabetes and high blood pressure, and to delay the progression of emphysema.
. |
